Aeterna Zentaris Inc.
| NASDAQ: AEZS | Healthcare / Biotechnology / USA |
| 2.24 | +0.1350 | +6.41% | Vol 15.02K | 1Y Perf -44.12% |
| Dec 6th, 2023 15:54 DELAYED |
| BID | 2.24 | ASK | 2.28 | ||
| Open | 2.14 | Previous Close | 2.11 | ||
| Pre-Market | - | After-Market | 2.30 | ||
| - - | 0.06 2.68% |
| Target Price | 28.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 1.15K | Finscreener Ranking | ★★★★★ 61.19 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★ 57.44 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★+ 62.08 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 33.33 | Earnings Rating | Strong Sell | |
| Market Cap | 10.88M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.24 | |
| Beta | 1.64 |
Today's Price Range 2.112.27 | 52W Range 1.364.00 | 5 Year PE Ratio Range -2.9021.90 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 13.13% | ||
| 1 Month | 43.59% | ||
| 3 Months | -10.04% | ||
| 6 Months | -21.40% | ||
| 1 Year | -44.12% | ||
| 3 Years | 495.74% | ||
| 5 Years | -38.96% | ||
| 10 Years | -97.96% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -49.51 | |||
ROE last 12 Months | -26.29 | |||
ROA (5Y Avg) | -4.78 | |||
ROA last 12 Months | -19.35 | |||
ROC (5Y Avg) | -333.45 | |||
ROC last 12 Months | -24.03 | |||
Return on invested Capital Q | -6.58 | |||
Return on invested Capital Y | -5.63 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.40 | ||||
| 0.35 | ||||
| 5.40 | ||||
| 9.90 | ||||
| -1.60 | ||||
| -3.54 | ||||
| 0.40 | ||||
| 10.18 | ||||
| -34 696 100.00 | ||||
| Forward PE | -0.61 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.40 | ||||
| 9.80 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -41 499.90 | ||||
| Leverage Ratio | 1.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 97.00 | ||||
| -344.60 | ||||
| -341.10 | ||||
| -710.50 | ||||
| -43.44 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.26M | ||||
| 0.67 | ||||
| 45.67 | ||||
| 26.21 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.61 | -0.85 | -39.34 |
| Q02 2023 | -0.87 | -0.52 | 40.23 |
| Q01 2023 | -1.07 | -0.88 | 17.76 |
| Q04 2022 | -0.93 | -0.84 | 9.68 |
| Q03 2022 | -0.68 | -0.70 | -2.94 |
| Q02 2022 | -0.68 | -0.87 | -27.94 |
| Q01 2022 | -0.50 | -0.50 | 0.00 |
| Q04 2021 | -0.50 | -0.50 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.97 | -44.78 | Negative |
| 12/2023 FY | -3.22 | -20.60 | Negative |
| 3/2024 QR | -0.81 | 7.95 | Positive |
| 12/2024 FY | -3.37 | -6.98 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.61 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 15.02K |
| Shares Outstanding | 4.86K |
| Shares Float | 4.86M |
| Trades Count | 138 |
| Dollar Volume | 32.81K |
| Avg. Volume | 10.41K |
| Avg. Weekly Volume | 10.11K |
| Avg. Monthly Volume | 11.19K |
| Avg. Quarterly Volume | 9.92K |
Aeterna Zentaris Inc. (NASDAQ: AEZS) stock closed at 2.24 per share at the end of the most recent trading day (a 6.41% change compared to the prior day closing price) with a volume of 15.02K shares and market capitalization of 10.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aeterna Zentaris Inc. CEO is Klaus Paulini.
The one-year performance of Aeterna Zentaris Inc. stock is -44.12%, while year-to-date (YTD) performance is -29.56%. AEZS stock has a five-year performance of -38.96%. Its 52-week range is between 1.3601 and 4, which gives AEZS stock a 52-week price range ratio of 33.33%
Aeterna Zentaris Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 0.35, a price-to-sale (PS) ratio of 5.40, a price to cashflow ratio of 9.90, a PEG ratio of -, a ROA of -19.35%, a ROC of -24.03% and a ROE of -26.29%. The company’s profit margin is -43.44%, its EBITDA margin is -341.10%, and its revenue ttm is $3.26 Million , which makes it $0.67 revenue per share.
Of the last four earnings reports from Aeterna Zentaris Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Aeterna Zentaris Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aeterna Zentaris Inc. is Strong Buy (1), with a target price of $28, which is +1 150.00% compared to the current price. The earnings rating for Aeterna Zentaris Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aeterna Zentaris Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aeterna Zentaris Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 33.43, ATR14 : 0.15, CCI20 : 105.70, Chaikin Money Flow : 0.23, MACD : 0.11, Money Flow Index : 69.95, ROC : 34.94, RSI : 68.34, STOCH (14,3) : 96.16, STOCH RSI : 1.00, UO : 57.17, Williams %R : -3.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aeterna Zentaris Inc. in the last 12-months were:
Aeterna Zentaris Inc.
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.
CEO: Klaus Paulini
Telephone: +1 843 900-3223
Address: 315 Sigma Drive, Summerville 29486, SC, US
Number of employees: 11
TipRanks News for AEZS
Fri, 14 Jul 2023 10:30 GMT Analysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS) and Alnylam Pharma (ALNY)
- TipRanks. All rights reserved.
